Aegis Restates ‘Buy’ Rating on Shares of Rosetta Genomics Ltd. (NASDAQ: ROSG)
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a company in the business of developing and commercializing MicroRNA-based and other molecular diagnostics, recently had its ‘Buy’ rating restated by Aegis Capital Corp. (http://nnw.fm/LV2Yy) with a price target of $3.50 per share. This was based on Aegis’ 2017 revenue estimate of $17.7 million with a multiple of 4X. The company update was released after Rosetta Genomics Ltd. announced a new collaboration to determine biomarkers that can predict response to Opdivo, a PD-1 immunotherapy. In addition to the above, Aegis Capital Corp. announced expectations for Rosetta Genomics’ cash deliverables to be over $9 million by…